BACKGROUND. Over the past decade, a number of new therapeutic agents have become
available in the treatment of metastatic breast cancer (MBC). This study characterized the use …

Background: Patient-level surveillance of antimicrobial use (AMU) in Canadian hospitals
empowers the reduction of inappropriate AMU and was piloted in 2017 among 14 hospitals in …

… Suzanne Malfair corresponding author Suzanne Malfair, BSc(Pharm), ACPR, PharmD,
FCSHP, BCPS, is Coordinator, Clinical Pharmacy Services, with Lions Gate Hospital and The …

OBJECTIVE: To characterize cefuroxime and cefuroxime axetil use under the influence of a
parenteral-to-oral (iv—po) stepdown program. DESIGN: Open single-center retrospective …

Background: Raltitrexed was developed as a direct and specific inhibitor of thymidylate
synthase. Early clinical trials showed similar activity to 5-fluorouracil (5-FU), mainly in metastatic …

To assess the costs of treating patients with incurable breast cancer, all health system costs
during the interval from diagnosis of first recurrence or metastasis until death for 75 female …

Introduction The British Columbia Ministry of Health launched a Smoking Cessation
Program on September 30, 2011, providing financial coverage for smoking cessation …

Purpose. Natural health products (NHP) are commonly used by cancer patients. The provision
of better information on NHP may improve the patient satisfaction and quality of life. We …

The first European conference on the economics of cancer was held in Brussels, Belgium
on November 19-21, 1997. This international meeting was organized under the European …

Transient nasopharyngeal discomfort induced by cyclophosphamide infusion has been
described in a few previous case reports. There is a theory that these adverse effects may have a …